Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Fennec Pharmaceuticals (FENC) Operating Margin (2020 - 2025)

Fennec Pharmaceuticals filings provide 4 years of Operating Margin readings, the most recent being 16.06% for Q4 2025.

  • On a quarterly basis, Operating Margin rose 2785.0% to 16.06% in Q4 2025 year-over-year; TTM through Dec 2025 was 3.4%, a 880.0% decrease, with the full-year FY2025 number at 3.39%, down 880.0% from a year prior.
  • Operating Margin hit 16.06% in Q4 2025 for Fennec Pharmaceuticals, up from 1.52% in the prior quarter.
  • In the past five years, Operating Margin ranged from a high of 54.16% in Q1 2024 to a low of 314.25% in Q1 2023.
  • Median Operating Margin over the past 3 years was 17.14% (2023), compared with a mean of 51.12%.
  • Biggest five-year swings in Operating Margin: soared 36841bps in 2024 and later tumbled -6339bps in 2025.
  • Fennec Pharmaceuticals' Operating Margin stood at 18.67% in 2023, then soared by 37bps to 11.79% in 2024, then surged by 236bps to 16.06% in 2025.
  • The last three reported values for Operating Margin were 16.06% (Q4 2025), 1.52% (Q3 2025), and 28.31% (Q2 2025) per Business Quant data.